Research news

Research news

15 January 2018

STUDY: Haider KS, Haider A, Doros G, Traish A. Long-Term Testosterone Therapy Improves Urinary and Sexual Function, and Quality of Life in Men with Hypogonadism: Results from a Propensity Matched Subgroup of a Controlled Registry Study. J Urol. 2018;199(1):257-265.

It is well documented that hypogonadism (testosterone deficiency) is associated with obesity, metabolic syndrome, reduced libido, erectile dysfunction and orgasmic dysfunction, and that testosterone therapy in these men improves cardiometabolic and sexual function.

However, concern remains that testosterone therapy may worsen lower urinary tract symptoms (LUTS) by possibly causing benign prostatic hyperplasia (BPH), although few major adverse events have been reported.

Read article
15 December 2017

Pastuszak AW, Kohn TP, Estis J, Lipshultz LI. Low Plasma Testosterone Is Associated With Elevated Cardiovascular Disease Biomarkers. The journal of sexual medicine. 2017;14(9):1095-1103.

The heightened fear of increased risk of heart attack and stroke with testosterone therapy was mainly caused by two high profile but flawed studies. Even though many new studies have refuted these alleged cardiovascular risks and even demonstrated that testosterone therapy is associated with a reduced cardiovascular risk, concern still remains among both physicians and the general population alike.

Read article
15 November 2017

Wolf J, Keipert D, Motazedi H, Ernst M, Nettleship J, Gooren L. Effectiveness and tolerability of parenteral testosterone undecanoate: a post-marketing surveillance study. The Aging Male: the official journal of the International Society for the Study of the Aging Male. 2017;20(4):225-234.

Read article
15 October 2017

Hackett G, Kirby M, Edwards D, Jones TH, Rees J, Muneer A. UK policy statements on testosterone deficiency. Int J Clin Pract. 2017;71(3-4).

Testosterone deficiency (also known as hypogonadism) and its treatment is a medical issue that has long been neglected, despite causing significant physiological and psychological health complications among affected men. Longstanding dogmatic fears about prostate cancer and more recent misleading studies alluding to heart attack and stroke risk, has made testosterone treatment a controversial topic.

Read article
15 September 2017

Dos Santos MR, Sayegh AL, Bacurau AV, et al. Effect of Exercise Training and Testosterone Replacement on Skeletal Muscle Wasting in Patients With Heart Failure With Testosterone Deficiency. Mayo Clin Proc. 2016;91(5):575-586.

Read article
15 August 2017

Sharma, R., et al., Normalization of Testosterone Levels After Testosterone Replacement Therapy Is Associated With Decreased Incidence of Atrial Fibrillation. J Am Heart Assoc, 2017. 6(5)

While the effect of testosterone treatment on cardiovascular health is a topic of ongoing debate, a growing body of evidence is refuting the widespread belief that testosterone treatment supposedly is harmful in terms of cardiovascular risk.

Here we report the results of a study, published in the Journal of the American Heart Association, which investigated the effect of testosterone treatment on the incidence of atrial fibrillation in hypogonadal men with documented low testosterone levels.

KEY POINTS

Read article
15 July 2017

Could Testosterone Replacement Therapy in Hypogonadal Men Ameliorate Anemia, a Cardiovascular Risk Factor? An Observational, 54-Week Cumulative Registry Study. Zhang LT, Shin YS, Kim JY, Park JK. J Urol. 2016;195(4 Pt 1):1057-1064.

Anemia is a common concern among the elderly; after the age of 50 years, anemia prevalence increases rapidly, especially in men. In community studies, the prevalence of anemia in older men has been reported to range from 11% 1 to 28%. The decline of hemoglobin and development of anemia with age is not part of "normal aging"; it is a sign of health deterioration and disease.

Read article
15 June 2017

Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis Following Testosterone Therapy. Sex Med Rev. 2017 [May 16, Epub ahead of print]

In discussions about side effects of testosterone treatment, prostate cancer and heart disease get most attention. However, as we have described in several study reports published here in the “Research News” section, the widespread fear of prostate cancer and heart disease is unfounded and not supported by medical research.

Read article
15 May 2017

Storer TW, Basaria S, Traustadottir T, et al. Effects of testosterone supplementation for 3 years on muscle performance and physical function in older men. J Clin Endocrinol Metab. 2017;102(2):583-593.

Declining testosterone levels – which is commonly seen in men as they get older - are associated with reduced lean body mass, muscle strength, and self-reported and performance-based measures of physical function. Evidence for a causal relationship between testosterone levels and lean body (muscle) mass comes from intervention studies which have shown that testosterone treatment consistently increases whole-body and appendicular lean body mass (which is a proxy for muscle mass).

Read article
15 April 2017

Yassin A, Salman M, Talib RA, Yassin DJ. Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register. The aging male: the official journal of the International Society for the Study of the Aging Male. 2017:1-9.

Historically, testosterone has almost been a synonym for prostate cancer, and therefore many men have been - and still are - denied testosterone therapy, despite having testosterone deficiency.

Read article
  • PP-NEB-ALL-0347-1

Copyright © 2019,
Bayer AG

This website is intended to provide information to an international audience outside the USA and UK.

Page last modified Wed, 05/02/2020

Bayer logo